COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ --
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan’s 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO.
Help employers find you! Check out all the jobs and post your resume.
